Science Corp raises $230M as it races to bring its brain implant to market

Science Corp, founded by Max Hodak, co-founder and former president of Neuralink, has raised $230 million in a Series C funding round, valuing the company at $1.25 billion. The startup is focused on bringing a brain-computer interface (BCI) product to market, specifically through the PRIMA implant, which it acquired from French company Pixium Vision in 2024. Science Corp has refined the technology and completed clinical trials involving 47 patients in Europe and the U.S., with 80% showing meaningful improvement in visual acuity, enabling them to read letters, numbers, and words. Hodak claims this is the first definitive demonstration of restored fluent reading ability in blind patients. The company has submitted a CE mark application for PRIMA in the European Union, anticipating approval by mid-2026, with Germany likely to be the first market due to its established pathways for early access to new medical technologies. Regulatory discussions with the U.S. FDA are ongoing. Science